SGLT-2 Inhibitors, An Issue of Heart Failure Clinics: The Clinics: Internal Medicine, cartea 18-4
Editat de Deepak L. Bhatt, Ragavendra R. Baligaen Limba Engleză Hardback – 10 oct 2022
Din seria The Clinics: Internal Medicine
- 5% Preț: 545.29 lei
- 70% Preț: 186.42 lei
- 5% Preț: 403.22 lei
- 5% Preț: 547.09 lei
- 5% Preț: 547.44 lei
- 5% Preț: 518.41 lei
- 5% Preț: 518.62 lei
- 5% Preț: 518.67 lei
- 5% Preț: 518.96 lei
- 5% Preț: 519.44 lei
- 5% Preț: 517.98 lei
- 5% Preț: 519.60 lei
- 5% Preț: 573.62 lei
- 5% Preț: 403.11 lei
- 5% Preț: 402.77 lei
- 5% Preț: 282.65 lei
- 5% Preț: 403.05 lei
- 5% Preț: 388.01 lei
- 5% Preț: 402.97 lei
- 5% Preț: 463.34 lei
- 5% Preț: 460.60 lei
- 5% Preț: 403.45 lei
- 5% Preț: 405.53 lei
- 5% Preț: 402.77 lei
- 5% Preț: 460.69 lei
- 5% Preț: 462.57 lei
- 5% Preț: 295.31 lei
- 5% Preț: 448.61 lei
- 5% Preț: 506.70 lei
- 5% Preț: 402.08 lei
- 5% Preț: 402.52 lei
- 5% Preț: 402.52 lei
- 5% Preț: 519.15 lei
- 5% Preț: 518.39 lei
- 5% Preț: 601.65 lei
- 5% Preț: 518.21 lei
- 5% Preț: 518.09 lei
- 21% Preț: 449.32 lei
- 21% Preț: 447.98 lei
- 5% Preț: 576.44 lei
- 5% Preț: 576.17 lei
- 5% Preț: 577.92 lei
- 5% Preț: 576.94 lei
- 5% Preț: 570.07 lei
- 5% Preț: 576.11 lei
- 5% Preț: 686.25 lei
- 5% Preț: 547.43 lei
- 5% Preț: 745.38 lei
- 5% Preț: 576.27 lei
- 5% Preț: 579.22 lei
Preț: 432.30 lei
Preț vechi: 455.05 lei
-5% Nou
Puncte Express: 648
Preț estimativ în valută:
82.75€ • 86.87$ • 68.35£
82.75€ • 86.87$ • 68.35£
Carte tipărită la comandă
Livrare economică 24 ianuarie-07 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780323960465
ISBN-10: 0323960464
Pagini: 240
Dimensiuni: 178 x 254 mm
Greutate: 0.54 kg
Editura: Elsevier
Seria The Clinics: Internal Medicine
ISBN-10: 0323960464
Pagini: 240
Dimensiuni: 178 x 254 mm
Greutate: 0.54 kg
Editura: Elsevier
Seria The Clinics: Internal Medicine
Cuprins
Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors
Renoprotective Effects of SGLT2 Inhibitors
SGLT2 Inhibitors in Type 2 Diabetes Mellitus
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection
SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction
SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits
Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events
SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature
Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease
SGLT2 Inhibitors and Safety in Older Patients
Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk
Renoprotective Effects of SGLT2 Inhibitors
SGLT2 Inhibitors in Type 2 Diabetes Mellitus
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection
SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction
SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits
Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events
SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature
Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease
SGLT2 Inhibitors and Safety in Older Patients
Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk